Cardiac Biomarkers Market Outlook by Type (Troponins, Myocardial Muscle Creatine Kinase, Myoglobin, BNPs, IMA, ALT/AST), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis), Testing Location (Laboratory Testing, Point-of-Care Testing) – Global Industry Demand Forecast to 2030

Market Overview

The global cardiac biomarkers market size was $8,459.6 million in 2021, and it is expected to generate $20,718.8 million by 2030, advancing with a robust CAGR of 10.5% during 2021–2030. This can be attributed to the increasing incidence of acute coronary syndrome (ACS), technological advancements in cardiac biomarkers, growing demand for point-of-care testing kits, and need for high specificity in the identification of cardiac disorders, particularly myocardial infarctions.

Additionally, the rising investments in biomarker research, increasing aging population, and surging incidence of CVDs due to the changing lifestyle are set to drive the market in the upcoming years.

Troponin Generates Majority of Revenue

Troponin accounted for the major revenue share of, over 35%, in 2021 in the market, and this category is expected to grow with a robust CAGR during the forecast period. This is due to the extraordinary specificity and capacity of their protein complex to help recognize cardiac problems, such as ACS, accurately. Additionally, the high prevalence of myocardial infarction will drive the market, as troponin is now the most-common tool to detect this condition. Furthermore, the myocardial muscle creatine kinase category will grow with a significant CAGR, followed by troponin, during the forecast period.

Additionally, cardiac test kits include a variety of combined tests that identify the existence of biomarkers, thus making the identification of cardiac disorders easier. The growing demand for these kits is a result of the quick diagnosis that can be achieved with them, which ultimately allows for faster treatments. Essentially, they aid in the diagnosis of chest discomfort and the identification of risk factors before adverse cardiac events take place.

Increasing Prevalence of CVDs Boosts Demand for Cardiac Biomarkers

The market for cardiac biomarkers is growing due to the rising prevalence of CVDs. According to the WHO, approximately 18 million deaths globally are caused by CVDs each year, which is 31% of all fatalities.

Hence, market players are aiming to offer test kits that help in the detection of biomarkers that enable a better understanding of the pathogenesis of CVDs. Major biomarkers discovered in recent years include B-type natriuretic peptide, C-reactive protein (CRP), N-terminal prohormone BNP, lipoprotein-associated phospholipase A2, and cystatin C. The increasing use of biomarkers in risk assessment and ACS diagnosis is driving the cardiac biomarkers market advance.

Laboratory Testing Accounts for Higher Revenue

Laboratory testing accounts for the larger revenue share, of around 60%, and this category is expected to maintain its position during 2021–2030. This is due to the increase in the healthcare spending and the number of reforms for healthcare infrastructure improvement, rise in the disposable income, and the government and private sectors’ initiatives aimed at preventing heart diseases.

The point-of-care testing category will grow with the higher CAGR during the forecast period, because doctors are increasingly adopting this approach to monitor patients with chest pain in critical care centers.

Explore more about this report - Request free sample pages

Myocardial Infarction Is Highest Revenue Contributor to Market

Myocardial infarction is the highest revenue contributor, with around $3.0 billion, in 2021, and this category is further expected to dominate the market during the forecast period. This is due to its rising incidence globally because of the changing lifestyles, unhealthy food, excessive smoking, and coronary artery disease. Furthermore, the surge in the demand for biomarker tests for the early detection of heart failure is the key factor set to boost the cardiac biomarkers market growth in the coming years.

North America Dominates Market

The North American cardiac biomarkers market accounted for the largest revenue share, of over 35%, in 2021. The dominance of the region can be attributed to the increasing usage of biomarkers for precision medicine, different growth strategies implemented by market players, and increasing adoption of biomarkers for the detection of cardiac diseases.

• The U.S. contributes the majority of the revenue to the regional market as it is the base for several market players and accounts for a high R&D expenditure on the healthcare sector.

APAC will be the fastest-growing market for such biomarkers, with a CAGR of around 11%, during the forecast period. This can be attributed to the growing healthcare infrastructure, various government schemes for the healthcare sector, high investment by market giants, high prevalence of cardiac diseases, and rising aging population.

• China holds the largest regional cardiac biomarkers market share, and it will witness significant growth in the coming years. The high morbidity and mortality due to CVDs, government’s Healthy China 2030 plan, and availability of advanced imaging, coronary stenting, and other technologies will boost the market growth in the country.
• India is the most-significant contributor to the market, following China, in the region. This is due to the rising cases of heart failure in adults because of the evolving lifestyles, improvements in specialized treatment approaches, and government schemes supporting the healthcare sector.

In addition, Europe holds a significant revenue share in the global market due to the presence of prominent research institutions and market players. Furthermore, the industry growth can be ascribed to the rising number of collaborations between regional universities and biomarker providers, governments and market players’ R&D initiatives related to biomarkers, and the strong efforts being taken to create awareness about the benefits of biomarkers.

Strategic Development of Market Players

To maintain a strong market position, players have adopted several strategies, including product launches, collaborations, partnerships, acquisitions, and investments. For instance:

• In April 2021, F. Hoffmann-La Roche Ltd. announced five new applications for two essential cardiac biomarkers that leverage Elecsys advanced technologies: high-sensitivity troponin T and N-terminal pro-brain natriuretic peptide test.
• In April 2021, Siemens Healthineers launched the Atellica VTLi patient-side immunoassay analyzer, which gives high-sensitivity cardiac troponin I (hs-cTnI) testing results in eight minutes, with a fingerstick blood sample.

Key Players in Cardiac Biomarkers Market Are:

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• bioMérieux Inc.
• Creative Diagnostics
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories Inc.
• Siemens Healthineers

Market Size Breakdown by Segment

The study offers a comprehensive market segmentation analysis along with market estimation for the period 2017-2030.

Based on Type

• Troponins
• Myocardial Muscle Creatine Kinase
• Myoglobin
• BNPs
• IMA
• ALT/AST

Based on Application

• Myocardial Infarction  
• Congestive Heart Failure
• Acute Coronary Syndrome
• Atherosclerosis

Based on Testing Location

• Laboratory Testing
• Point-of-Care Testing  

Geographical Analysis

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa
  • Saudi Arabia
  • South Africa